Celldex Therapeutics, Inc. shares tumbled yesterday on heavy ... The nimble investor can leverage our analysis and …
Celldex Therapeu has traded 7.0 million shares thus far today, vs. average volume of 3.6 million shares per day. The stock has outperformed the Dow (-53.5% to the Dow's -100.0%) and underperformed the S&P 500 (-53.5% to the S&P's …
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Celldex (NASDAQ: CLDX) 49% …
Celldex Therapeutics Inc. (CLDX ... Recent event: -- On March 27, 2018, the Company closed the public offering of common stock and full exercise of underwriters' option to purchase additional shares. The shares were priced at $7.50 …
Deutsche Bank very positive on four companies in the space, and all are rated Buy. Palo Alto Networks This stock was a momentum trader's dream before crashing …
Hampton, NJ-based Celldex fell even deeper into penny stock territory, plunging …
The setback compounds the effect felt by a March 2016 failure of Celldex's glioblastoma vaccine Rintega in Phase 3, which led to a then 50% drop in the company's stock. The company now places it hopes on varlilumab, a CD27 agonist …
Investors in Celldex Therapeutics, Inc. CLDX need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 20 th 2018 $2.00 Put had some of the highest implied volatility of all equity …